Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
基本信息
- 批准号:7502209
- 负责人:
- 金额:$ 4.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2010-09-29
- 项目状态:已结题
- 来源:
- 关键词:2&apos-deoxyadenosineABCB1 geneABCC1 geneAddressAdipose tissueAminesAmino AcidsAnimalsAreaAromatic Polycyclic HydrocarbonsBenz(a)AnthracenesBenzo(a)pyreneBindingBiologicalBiological AssayCYP1A1 geneCYP3A4 geneCYP3A5 geneCancer EtiologyCarcinogensCationsCattleCause of DeathCell LineCell NucleusCellsCharacteristicsCoalCpG IslandsCultured CellsCytochrome P450CytochromesDNADNA AdductionDNA AdductsDNA DamageDataDeoxyguanosineDevelopmentDimethyl SulfoxideDioxinsDrug Delivery SystemsDrug Metabolic DetoxicationEnvironmental CarcinogensEnvironmental PollutantsEnzymesEpoxide hydrolaseExperimental ModelsExposure toFamily memberFire - disastersFoodGarbageGasesGenomicsGlutathioneGlutathione S-TransferaseGlycolGlycoproteinsGuanineHepatocyteHumanHuman MilkHydrolysisIn VitroIndividualIndividual DifferencesInternational Agency for Research on CancerItraconazoleKidneyLinkLiquid ChromatographyLiteratureLiverLungMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of urinary bladderMass Spectrum AnalysisMeatMediatingMessenger RNAMetabolicMetabolic ActivationMetabolic PathwayMetabolismMethodologyMethodsModelingMonitorMultidrug Resistance Associated Protein 1MusMutationNamesNatureNull LymphocytesOilsOxidesP-GlycoproteinPathway interactionsPharmaceutical PreparationsPhasePlayPoint MutationPromoter RegionsProtein IsoformsProtein p53ProteomicsPublic HealthPyrenesRNA InterferenceReactionReportingResearchReverse Transcriptase Polymerase Chain ReactionRoleSkinSmall Interfering RNASmokeSmokerStable Isotope LabelingTP53 geneTestingTobaccoTobacco smokeToxic effectTransfectionTransferaseUnited StatesUnited States Dept. of Health and Human ServicesWestern BlottingWood materialWorkplaceadductanticancer researchbasebenzanthracenecarbonyl reductase (NADPH)carcinogenesiscigarette smokingcigarette smokingcytochrome P450 3Aextracellularfluoranthenehepatoma cellinhibitor/antagonistinsightlung carcinogenesismultidrug resistance-associated protein 2novelnovel therapeuticspreventprotein expressionpyreneresearch studystable isotopetobacco exposuretranscription factor
项目摘要
DESCRIPTION (provided by applicant): In this proposed research, benzo[a]pyrene (B[a]P) and it's metabolites, will be used as model compounds to determine the major metabolic pathways of PAHs in lung carcinogenesis. It is generally accepted that cytochrome P4501A1, CYP1A1, is primarily responsible for the metabolism of B[a]P to 7,8-dihydroxy-9,10- epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (B[a]PDE), the ultimate DNA-adduct forming, carcinogenic reactive metabolite; thus connecting CYP1A1 to the toxicological effects of this environmental carcinogen. DNA-adduct formation has been detected at CpG islands located in the promoter region of the tumor suppressor p53. Inactivation of p53 by point mutations is seen in over 40% of all cancers. However, in preliminary research using H358, human bronchoalveolar lung cells, it was found that DNA-adduct levels were higher in non-treated CYP1A1/1B1 null cells compared to H358 cells in which CYP1A1 expression was induced with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). This data correlates with literature results of CYP1A1 KO mice stuides in which it was determined that CYP1A1 conferred a protective rather than a toxic effect. This is indicative of the metabolic activity of another CYP in the metabolism of B[a]P. Several other CYP enzymes are capable of catalyzing this metabolism. Preliminary data has also indicated that TCDD may have an effect on the transport of B[a]P-reactive metabolites. It is known that TCDD is able to induce several of the ABCC drug transporter family members; therefore, explaining why less DNA-adduct formation is observed in lung cells pretreated with TCDD . This proposal, which has two aims, will identify the predominate CYP responsible for B[a]P metabolism in the lung and determine the role of B[a]PDE transporters in DNA-adduct formation in lung cells. A stable isotope dilution LC-MRM/MS method, previously developed, will be used for DNA-adduct quantification. DNA-adduct levels will be correlated to mRNA and protein expression determined by RT-PCR and a novel quantitative proteomics method, SI LAC. CYPs including 1A1, 1B1, 1A2, 2B6, 2E1, 2J2, 3A4, and 3A5 will be investigated. DNA-adduct formation will also be monitored in lung cells in which drug transporter expression has been inhibited by siRNA. Continuing research in this area will provide exciting new therapeutic strategies (drug targets) that can be employed to prevent PAH-mediated DNA damage. Relevance to public health: Cigarette smoke is known to cause 90% of lung cancer, but only 10% of smokers develop lung cancer. Examination of alternative CYP metabolism and B[a]PDE transport in lung cells will provide an experimental model to explore whether inter-individual differences in CYP metabolism and transport contribute to these phenomenon.
描述(由申请人提供):在这项拟议的研究中,苯并[a]芘(B[a]P)及其代谢物将用作模型化合物,以确定多环芳烃在肺癌发生中的主要代谢途径。人们普遍认为细胞色素 P4501A1(CYP1A1)主要负责 B[a]P 代谢为 7,8-二羟基-9,10-环氧-7,8,9,10-四氢苯并[a]芘(B [a]PDE),最终形成 DNA 加合物的致癌反应性代谢物;从而将 CYP1A1 与这种环境致癌物的毒理学作用联系起来。位于肿瘤抑制因子 p53 启动子区域的 CpG 岛已检测到 DNA 加合物形成。超过 40% 的癌症均因点突变而导致 p53 失活。然而,在使用人支气管肺泡肺细胞 H358 的初步研究中,发现与用 2、3、7、8 诱导 CYP1A1 表达的 H358 细胞相比,未处理的 CYP1A1/1B1 无效细胞中的 DNA 加合物水平较高。 -四氯二苯并-对-二恶英(TCDD)。该数据与 CYP1A1 KO 小鼠研究的文献结果相关,其中确定 CYP1A1 具有保护作用而不是毒性作用。这表明 B[a]P 代谢中另一种 CYP 的代谢活性。其他几种 CYP 酶能够催化这种代谢。初步数据还表明,TCDD 可能对 B[a]P 反应性代谢物的转运有影响。众所周知,TCDD 能够诱导多种 ABCC 药物转运蛋白家族成员;因此,解释了为什么在用 TCDD 预处理的肺细胞中观察到较少的 DNA 加合物形成。该提案有两个目标,将确定负责肺中 B[a]P 代谢的主要 CYP,并确定 B[a]PDE 转运蛋白在肺细胞 DNA 加合物形成中的作用。先前开发的稳定同位素稀释 LC-MRM/MS 方法将用于 DNA 加合物定量。 DNA 加合物水平将与 RT-PCR 和新型定量蛋白质组学方法 SI LAC 测定的 mRNA 和蛋白质表达相关联。将研究包括 1A1、1B1、1A2、2B6、2E1、2J2、3A4 和 3A5 在内的 CYP。还将监测肺部细胞中 DNA 加合物的形成,其中药物转运蛋白的表达已被 siRNA 抑制。该领域的持续研究将提供令人兴奋的新治疗策略(药物靶点),可用于预防 PAH 介导的 DNA 损伤。与公共健康的相关性:已知 90% 的肺癌是由香烟烟雾引起的,但只有 10% 的吸烟者会患上肺癌。对肺细胞中替代 CYP 代谢和 B[a]PDE 转运的检查将提供一个实验模型,以探讨 CYP 代谢和转运的个体间差异是否导致这些现象。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stacy Lynn Gelhaus其他文献
Stacy Lynn Gelhaus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stacy Lynn Gelhaus', 18)}}的其他基金
LIMA: Lipid anti-Inflammatory Mediators in Asthma to reduce airway hyperresponsiveness in obese asthmatics
LIMA:哮喘中的脂质抗炎介质可减少肥胖哮喘患者的气道高反应性
- 批准号:
10369934 - 财政年份:2022
- 资助金额:
$ 4.96万 - 项目类别:
LIMA: Lipid anti-Inflammatory Mediators in Asthma to reduce airway hyperresponsiveness in obese asthmatics
LIMA:哮喘中的脂质抗炎介质可减少肥胖哮喘患者的气道高反应性
- 批准号:
10720482 - 财政年份:2022
- 资助金额:
$ 4.96万 - 项目类别:
The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology
硝酸盐/亚硝酸盐和共轭亚油酸补充剂对肥胖哮喘病理的影响
- 批准号:
9297207 - 财政年份:2016
- 资助金额:
$ 4.96万 - 项目类别:
The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology
硝酸盐/亚硝酸盐和共轭亚油酸补充剂对肥胖哮喘病理的影响
- 批准号:
9180182 - 财政年份:2016
- 资助金额:
$ 4.96万 - 项目类别:
Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
- 批准号:
7679487 - 财政年份:2007
- 资助金额:
$ 4.96万 - 项目类别:
Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
- 批准号:
7406263 - 财政年份:2007
- 资助金额:
$ 4.96万 - 项目类别:
相似国自然基金
N6-脱氧腺苷甲基化(6mA)介导辣椒疫霉对新型解偶联剂双苯菌胺(SYP-14288)的胁迫适应性机制研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:
高通透孔道和精确分子取向识别印迹微球选择性分离纯化2'-脱氧腺苷的研究
- 批准号:
- 批准年份:2020
- 资助金额:64 万元
- 项目类别:面上项目
基于MTH1底物设计的7-脱氮-2´-脱氧腺苷类似物的合成与抗肿瘤活性研究
- 批准号:81903425
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
以2ʹ-氯代喷司他丁与2ʹ-氨基-2ʹ-脱氧腺苷为模型的腺苷类抗生素组合的生物合成研究
- 批准号:31970052
- 批准年份:2019
- 资助金额:56 万元
- 项目类别:面上项目
乳液界面各向异性生长辅助构建单孔中空MMIPs选择性分离纯化2′-脱氧腺苷的研究
- 批准号:21706099
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Mechanisms of HIV-1 Hypersensitivity to Islatravir
HIV-1 对 Islatravir 过敏的机制
- 批准号:
10548541 - 财政年份:2022
- 资助金额:
$ 4.96万 - 项目类别:
A dual-purpose hu-mouse model for evaluating SIV and HIV cure strategies
用于评估 SIV 和 HIV 治疗策略的双用途人鼠模型
- 批准号:
10652685 - 财政年份:2022
- 资助金额:
$ 4.96万 - 项目类别:
Mechanisms of HIV-1 Hypersensitivity to Islatravir
HIV-1 对 Islatravir 过敏的机制
- 批准号:
10731747 - 财政年份:2022
- 资助金额:
$ 4.96万 - 项目类别:
Long-Acting Prevention Implantable System (LAPIS) for HIV Pre-ExposureProphylaxis (PrEP)
用于 HIV 暴露前预防 (PrEP) 的长效预防植入系统 (LAPIS)
- 批准号:
10348177 - 财政年份:2020
- 资助金额:
$ 4.96万 - 项目类别:
Salvage of the sulfur and carbon byproducts of S-adenosylmethionine metabolism in pathogenic bacteria
病原菌中S-腺苷甲硫氨酸代谢的硫和碳副产物的回收
- 批准号:
10163801 - 财政年份:2020
- 资助金额:
$ 4.96万 - 项目类别: